These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 23931567)
1. Enigmas regarding the true extent and impact of tyrosine kinase inhibitor-related cardiotoxicity. Ewer MS; Ewer SM Expert Opin Drug Saf; 2013 Sep; 12(5):611-4. PubMed ID: 23931567 [TBL] [Abstract][Full Text] [Related]
2. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future. Yang B; Papoian T J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. Yang B; Papoian T J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481 [TBL] [Abstract][Full Text] [Related]
4. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Hasinoff BB; Patel D Toxicol Appl Pharmacol; 2010 Dec; 249(2):132-9. PubMed ID: 20832415 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress. Gratia S; Kay L; Potenza L; Seffouh A; Novel-Chaté V; Schnebelen C; Sestili P; Schlattner U; Tokarska-Schlattner M Cardiovasc Res; 2012 Aug; 95(3):290-9. PubMed ID: 22461523 [TBL] [Abstract][Full Text] [Related]
7. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Hasinoff BB Toxicol Appl Pharmacol; 2010 Apr; 244(2):190-5. PubMed ID: 20045709 [TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use. Dasanu CA; Padmanabhan P; Clark BA; Do C Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002 [TBL] [Abstract][Full Text] [Related]
10. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Cheng H; Force T Prog Cardiovasc Dis; 2010; 53(2):114-20. PubMed ID: 20728698 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular toxicity of biologic agents for cancer therapy. Bhave M; Akhter N; Rosen ST Oncology (Williston Park); 2014 Jun; 28(6):482-90. PubMed ID: 25134321 [TBL] [Abstract][Full Text] [Related]
12. Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors. Vaidya T; Kamta J; Chaar M; Ande A; Ait-Oudhia S J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):401-418. PubMed ID: 29446053 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Chintalgattu V; Patel SS; Khakoo AY Hematol Oncol Clin North Am; 2009 Feb; 23(1):97-107, viii-ix. PubMed ID: 19248973 [TBL] [Abstract][Full Text] [Related]
15. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696 [TBL] [Abstract][Full Text] [Related]
16. Small molecule tyrosine kinase inhibitor and depression. Quek R; Morgan JA; George S; Butrynski JE; Polson K; Meyer F; Demetri GD; Block SD J Clin Oncol; 2009 Jan; 27(2):312-3. PubMed ID: 19064960 [No Abstract] [Full Text] [Related]
17. Drug toxicity: Cardiac safety index for TKIs. Crunkhorn S Nat Rev Drug Discov; 2017 Mar; 16(4):240. PubMed ID: 28356585 [No Abstract] [Full Text] [Related]